Jazz Pharmaceuticals Shares Outstanding 2007-2018 | JAZZ

Jazz Pharmaceuticals shares outstanding history from 2007 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Jazz Pharmaceuticals shares outstanding for the quarter ending September 30, 2018 were 0.062B, a 0.69% increase year-over-year.
  • Jazz Pharmaceuticals 2017 shares outstanding were 0.061B, a 0.89% decline from 2016.
  • Jazz Pharmaceuticals 2016 shares outstanding were 0.062B, a 1.85% decline from 2015.
  • Jazz Pharmaceuticals 2015 shares outstanding were 0.063B, a 0.67% increase from 2014.
Jazz Pharmaceuticals Annual Shares Outstanding
(Millions of Shares)
2017 61
2016 62
2015 63
2014 63
2013 62
2012 60
2011 47
2010 39
2009 30
2008 26
2007 14
2006 0
2005 0
Jazz Pharmaceuticals Quarterly Shares Outstanding
(Millions of Shares)
Q3 2018 62
Q2 2018 61
Q1 2018 61
Q4 2017 61
Q3 2017 61
Q2 2017 61
Q1 2017 61
Q4 2016 62
Q3 2016 62
Q2 2016 62
Q1 2016 63
Q4 2015 63
Q3 2015 63
Q2 2015 63
Q1 2015 63
Q4 2014 63
Q3 2014 63
Q2 2014 62
Q1 2014 59
Q4 2013 62
Q3 2013 62
Q2 2013 62
Q1 2013 62
Q4 2012 60
Q3 2012 61
Q2 2012 61
Q1 2012 58
Q4 2011 47
Q3 2011 47
Q2 2011 47
Q1 2011 46
Q4 2010 39
Q3 2010 42
Q2 2010 35
Q1 2010 35
Q4 2009 30
Q3 2009 31
Q2 2009 29
Q1 2009 29
Q4 2008 26
Q3 2008 27
Q2 2008 24
Q1 2008 24
Q4 2007 14
Q3 2007 24
Q2 2007 8
Q1 2007 0
Q4 2006 0
Q3 2006 13
Q2 2006 0
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $8.614B $1.619B
Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. Company's goal is to build a broad portfolio of products through a combination of internal development and acquisition/in-licensing activities and to utilize our specialty sales force to promote products in our target markets. They apply novel formulations and drug delivery technologies to known drug compounds, and compounds with the same mechanism of action or similar chemical structure as marketed products, to improve patient care by improving efficacy, reducing adverse side effects or increasing patient compliance relative to existing therapies. Based in Palo Alto, California, the company is committed to working closely with patients, patient advocacy groups and healthcare professionals.
Stock Name Country Market Cap PE Ratio
Shire (SHPG) Ireland $53.371B 11.43
Zoetis (ZTS) United States $44.331B 30.35
Grifols (GRFS) Spain $14.524B 17.73
Tilray (TLRY) United States $10.290B 0.00
Neurocrine Biosciences (NBIX) United States $8.160B 1799.60
Ionis Pharmaceuticals (IONS) United States $7.393B 0.00
Nektar Therapeutics (NKTR) United States $6.617B 9.49
Catalent (CTLT) United States $5.726B 24.02
Impax Laboratories (AMRX) United States $5.526B 0.00
Sage Therapeutics (SAGE) United States $5.355B 0.00
United Therapeutics (UTHR) United States $5.295B 8.66
Loxo Oncology (LOXO) United States $4.792B 0.00
Taro Pharmaceutical Industries (TARO) Israel $3.937B 14.58
FibroGen (FGEN) United States $3.437B 0.00
USANA Health Sciences (USNA) United States $2.884B 24.55
Endo (ENDP) Ireland $2.847B 4.36
Xencor (XNCR) United States $2.239B 0.00
Heron Therapeutics (HRTX) United States $2.084B 0.00
Madrigal Pharmaceuticals (MDGL) United States $2.000B 0.00
Aerie Pharmaceuticals (AERI) United States $1.949B 0.00
Endocyte (ECYT) United States $1.943B 0.00
TESARO (TSRO) United States $1.924B 0.00
Pacira Pharmaceuticals (PCRX) United States $1.924B 260.00
Ironwood Pharmaceuticals (IRWD) United States $1.846B 0.00
PTC Therapeutics (PTCT) United States $1.711B 0.00
Zogenix (ZGNX) United States $1.710B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.573B 19.24
Corcept Therapeutics (CORT) United States $1.503B 22.07
Theravance Biopharma (TBPH) Cayman Islands $1.454B 0.00
Spectrum Pharmaceuticals (SPPI) United States $1.413B 0.00
Portola Pharmaceuticals (PTLA) United States $1.329B 0.00
Tricida (TCDA) United States $1.318B 0.00
Esperion Therapeutics (ESPR) United States $1.300B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $1.179B 0.00
TherapeuticsMD (TXMD) United States $1.158B 0.00
ImmunoGen (IMGN) United States $0.892B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.863B 0.00
Radius Health (RDUS) United States $0.761B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.690B 0.00
Karyopharm Therapeutics (KPTI) United States $0.678B 0.00
Flexion Therapeutics (FLXN) United States $0.638B 0.00
Collegium Pharmaceutical (COLL) United States $0.578B 0.00
GlycoMimetics (GLYC) United States $0.515B 0.00
ChemoCentryx (CCXI) United States $0.514B 40.68
Rigel Pharmaceuticals (RIGL) United States $0.477B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $0.468B 0.00
Akebia Therapeutics (AKBA) United States $0.455B 0.00
Siga Technologies (SIGA) United States $0.448B 0.00
Odonate Therapeutics (ODT) United States $0.443B 0.00
Xeris Pharmaceuticals (XERS) United States $0.439B 0.00
Dova Pharmaceuticals (DOVA) United States $0.437B 0.00
ArQule (ARQL) United States $0.436B 0.00
OptiNose (OPTN) United States $0.425B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.423B 24.96
Aquestive Therapeutics (AQST) United States $0.421B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.412B 0.00
Dermira (DERM) United States $0.409B 0.00
Forty Seven (FTSV) United States $0.404B 0.00
CASI Pharmaceuticals (CASI) United States $0.391B 0.00
Zafgen (ZFGN) United States $0.364B 0.00
Aclaris Therapeutics (ACRS) United States $0.361B 0.00
Depomed (ASRT) United States $0.351B 13.07
Corbus Pharmaceuticals Holdings (CRBP) United States $0.347B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.346B 0.00
Mast Therapeutics (SVRA) United States $0.330B 0.00
Tapimmune (MRKR) United States $0.329B 0.00
Minerva Neurosciences (NERV) United States $0.327B 0.00
KalVista Pharmaceuticals (KALV) United States $0.324B 0.00
Aratana Therapeutics (PETX) United States $0.319B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.317B 0.00
Concert Pharmaceuticals (CNCE) United States $0.313B 0.00
Translate Bio (TBIO) United States $0.307B 0.00
Majesco Entertainment (PTE) United States $0.269B 0.00
Affimed (AFMD) Germany $0.266B 0.00
IMV INC (IMV) Canada $0.254B 0.00
Opexa Therapeutics (ACER) United States $0.249B 0.00
Lannett Co Inc (LCI) United States $0.233B 2.03
Tyme Technologies (TYME) United States $0.232B 0.00
Aldeyra Therapeutics (ALDX) United States $0.231B 0.00
Ocular Therapeutix (OCUL) United States $0.219B 0.00
MEI Pharma (MEIP) United States $0.216B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.212B 0.00
Galectin Therapeutics (GALT) United States $0.208B 0.00
Oasmia Pharmaceutical AB (OASM) Sweden $0.205B 0.00
Calithera Biosciences (CALA) United States $0.197B 0.00
Neon Therapeutics (NTGN) United States $0.197B 0.00
ElectroCore (ECOR) United States $0.192B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.186B 0.00
Ardelyx (ARDX) United States $0.186B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.181B 0.00
Marinus Pharmaceuticals (MRNS) United States $0.181B 0.00
Nature's Sunshine Products (NATR) United States $0.177B 0.00
Molecular Templates (MTEM) United States $0.173B 0.00
Redhill Biopharma (RDHL) Israel $0.168B 0.00
ContraFect (CFRX) United States $0.166B 0.00
MediWound (MDWD) Israel $0.162B 0.00
DURECT (DRRX) United States $0.144B 0.00
Jounce Therapeutics (JNCE) United States $0.144B 0.00
Recro Pharma (REPH) United States $0.141B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.140B 0.00
Melinta Therapeutics (MLNT) United States $0.139B 0.00
Champions Oncology (CSBR) United States $0.139B 0.00
Adherex Technologies (FENC) United States $0.137B 0.00
ProNAi Therapeutics (SRRA) Canada $0.127B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.123B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.122B 0.00
Cardiome Pharma (CORV) Canada $0.113B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.099B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.099B 0.00
CTI BioPharma (CTIC) United States $0.098B 0.00
Synergy Pharmaceuticals (SGYP) United States $0.097B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.082B 0.00
Iterum Therapeutics (ITRM) Ireland $0.081B 0.00
Infinity Pharmaceuticals (INFI) United States $0.080B 0.00
Otonomy (OTIC) United States $0.076B 0.00
Achaogen (AKAO) United States $0.076B 0.00
Nivalis Therapeutics (ALPN) United States $0.073B 0.00
BioLineRx (BLRX) Israel $0.071B 0.00
Natural Alternatives (NAII) United States $0.070B 6.85
KemPharm (KMPH) United States $0.067B 0.00
Immune Design (IMDZ) United States $0.066B 0.00
Novan (NOVN) United States $0.063B 0.00
Forward Pharma (FWP) Denmark $0.060B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.059B 0.00
Avenue Therapeutics (ATXI) United States $0.059B 0.00
Neos Therapeutics (NEOS) United States $0.058B 0.00
Genocea Biosciences (GNCA) United States $0.050B 0.00
Capnia (SLNO) United States $0.045B 0.00
Mannatechorporated (MTEX) United States $0.043B 0.00
Trillium Therapeutics (TRIL) Canada $0.043B 0.00
Heat Biologics (HTBX) United States $0.041B 0.00
SCYNEXIS (SCYX) United States $0.039B 0.00
Tokai Pharmaceuticals (NVUS) United States $0.038B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.036B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.036B 0.00
ProPhase Labs (PRPH) United States $0.035B 0.00
Lipocine (LPCN) United States $0.031B 0.00
Biomerica (BMRA) United States $0.027B 0.00
Onconova Therapeutics (ONTX) United States $0.025B 0.00
Xenetic Biosciences (XBIO) United States $0.024B 0.00
HANCOCK JAFFE (HJLI) United States $0.023B 0.00
Jaguar Animal Health (JAGX) United States $0.022B 0.00
Citius Pharmaceuticals (CTXR) United States $0.021B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.021B 0.00
Cyanotech (CYAN) United States $0.021B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.019B 0.00
Aviragen Therapeutics (VXRT) United States $0.019B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.019B 6.75
ESSA Pharma (EPIX) Canada $0.019B 0.00
Pain Therapeutics (PTIE) United States $0.019B 0.00
CollPlant Holdings Sponsored ADR (CLGN) Israel $0.018B 0.00
Shineco (TYHT) China $0.016B 1.60
Aradigm (ARDM) United States $0.015B 0.00
DelMar Pharmaceuticals (DMPI) Canada $0.014B 0.00
Regulus Therapeutics (RGLS) United States $0.013B 0.00
OncoGenex Pharmaceuticals (ACHV) United States $0.012B 0.00
Skyline Medical (AIPT) United States $0.012B 0.00
Midatech Pharma (MTP) United Kingdom $0.011B 0.00
Ohr Pharmaceuticals (OHRP) United States $0.010B 0.00
Apricus Biosciences (APRI) United States $0.008B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.007B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.007B 0.00
Bio-Path Holdings (BPTH) United States $0.006B 0.00
PharmAthene (ALT) United States $0.006B 0.00
Ritter Pharmaceuticals (RTTR) United States $0.004B 0.00
Bio Blast Pharma (ORPN) Israel $0.004B 0.00
Auris Medical Holding AG (EARS) Switzerland $0.003B 0.00
Intellipharmaceutics (IPCI) Canada $0.002B 0.00
RXi Pharmaceuticals (RXII) United States $0.001B 0.00
Advanced Accelerator Applications (AAAP) France $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00